Shukra Pharmaceuticals has closed its trading window for dealing in company securities starting October 1, 2026. This closure applies to promoters, directors, key managerial personnel, and connected persons ahead of the declaration of unaudited financial results for the quarter ended September 30, 2026.

The restriction remains in effect until 48 hours after the announcement of the Q2FY27 financial results. The move is pursuant to Clause 4(2) of Schedule B read with Regulation 9 of the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015.

Regulatory Compliance and Scope

The closure covers all designated persons, including dependants and immediate relatives as defined in the company's Insider Trading Code. It also extends to connected persons who may have access to unpublished price-sensitive information.

The company cited SEBI Circular No. SEBI/HO/ISD/ISD-SEC-4/P/CIR/2022/107 dated August 5, 2022, and SEBI/HO/ISD/ISD-PoD-2/P/CIR/2023/124 dated July 19, 2023, as the basis for this procedural step. These circulars reinforce the internal procedures for regulating trading by insiders during sensitive periods.

Upcoming Board Meeting

The date for the Board Meeting to approve the unaudited financial results for the quarter ended September 30, 2026, will be announced in due course. Until then, all relevant parties are advised to refrain from entering into any transactions involving the securities of the company.

This standard compliance measure ensures that no insider trading occurs while material financial information is being finalized and prepared for public disclosure.

Shukra Pharmaceuticals issued a corrigendum on September 22, 2026, to its postal ballot notice dated August 22, 2026. The revision substitutes the original Independent Auditor's Certificate with a revised version dated September 16, 2026, to comply with specific numerical disclosure requirements under Regulation 45 of the SEBI (LODR) Regulations, 2015.

The original notice sought shareholder approval for altering the Main Object Clause of the Memorandum of Association and changing the company name from "Shukra Pharmaceuticals Limited" to "Shukra Medtech Limited." The corrigendum was necessitated by observations from BSE Limited regarding the format of the auditor's certificate attached to the explanatory statement.

Revised Auditor's Certificate Details

The statutory auditors, M/s Shah Sanghvi & Associates, Chartered Accountants, issued the revised certificate to align with the mandated layout. The certificate confirms that at least one year has elapsed since the last name change. It also certifies compliance with Regulation 45(1)(b), which requires that at least fifty percent of total revenue in the preceding one-year period be accounted for by the new activity suggested by the new name, or that at least fifty percent of assets are invested in the new activity.

The revised certificate provides detailed financial data for the period from July 1, 2025, to June 30, 2026. While income from the new medical technology activity was nil, the company demonstrated asset investment compliance.

Shareholder Voting Instructions

The remote e-voting period commenced on August 28, 2026, and concludes on September 26, 2026. To ensure transparency following the issuance of the corrigendum, shareholders who have already voted are permitted to cast their vote again via the NSDL e-voting system.

• If a shareholder votes again during the active window, the latest vote will supersede and cancel the previous vote.
• Shareholders who do not wish to change their previously recorded vote need not take any action; their initial vote remains valid.
• The corrigendum and revised certificate are available on the company website and stock exchange platforms.

What the Numbers Show

The financial data reveals a divergence between revenue generation and asset allocation regarding the proposed business shift. For the fiscal year ending June 30, 2026, the company reported zero income from its new medical technology activity, with 100% of revenue derived from its legacy pharmaceutical operations. However, it met the regulatory threshold for name change by investing ₹5,058.31 lakh, representing 51.04% of its total assets, into the new medical technology line of business. This indicates a strategic capital deployment ahead of operational revenue realization in the new segment.